Summary (tl;dr)

Robert F. Kennedy Jr., as the U.S. Secretary of Health and Human Services (HHS), has officially ended the Emergency Use Authorizations (EUAs) for COVID-19 drugs, biological products, and medical devices, stating that the emergency conditions that necessitated them no longer exist.

Essential Background

In 2020, at the onset of the COVID-19 pandemic, the U.S. Department of Health and Human Services (HHS) initiated Emergency Use Authorizations (EUAs) to expedite the availability of critical medical countermeasures, including diagnostics, treatments, and vaccines, to address the public health emergency. These authorizations allowed medical products to be used based on less comprehensive data than required for full FDA approval, reflecting the urgent need during the crisis. Robert F. Kennedy Jr. assumed the role of HHS Secretary in 2025, following his nomination by President-elect Donald Trump in late 2024. He has been a vocal critic of mainstream public health policies and has expressed skepticism regarding vaccine safety.

The Full Story

On June 30, 2026, HHS Secretary Robert F. Kennedy Jr. formally terminated the Emergency Use Authorization (EUA) declarations that applied to COVID-19-related drugs, biological products, and medical devices. According to the HHS, the decision stems from the determination that the circumstances which originally justified these emergency authorities are no longer present. The department highlighted that FDA-approved, cleared, and licensed products are now widely accessible through traditional regulatory pathways, diminishing the necessity for EUA products. The termination for drugs and biological products will become effective on June 29, 2027, while for medical devices, it will take effect on December 26, 2026, allowing for advance notice periods to facilitate an orderly transition for manufacturers and healthcare providers. This action aligns with Secretary Kennedy's broader efforts to restructure HHS, which have involved significant reductions in staff and research funding, and controversial alterations to federal vaccine guidelines.

Why It Matters

The termination of COVID-19 EUAs marks a notable shift in the U.S.'s approach to public health emergencies, signaling a return to traditional regulatory approval processes. This move is particularly significant given Secretary Kennedy's past and current controversial stances on public health, including his skepticism about vaccines and his "Make America Healthy Again" (MAHA) initiative. Critics argue that his actions and policies, including these EUA changes, could erode public trust in scientific institutions and potentially compromise the nation's readiness for future health crises.

Geographic Location

• Washington, D.C., District of Columbia, United States (HHS Secretary Robert F. Kennedy Jr. signed determinations terminating COVID-19 Emergency Use Authorization declarations)